Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25009502 | 0.90 | MEN1 (0.81) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL25010005 | 0.88 | MEN1 (0.78) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL25009091 | 0.79 | MEN1 (0.65) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL25010020 | 0.78 | TP53 (0.81) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL18184511 | 0.77 | TP53 (0.64) | MEN1KMT2APOLBTP53LMNA | |
| SCHEMBL25009227 | 0.75 | PKM (0.83) | POLBTP53LMNAPKMTHRB | |
| SCHEMBL25009491 | 0.75 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL18184455 | 0.74 | TP53 (0.67) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL16032121 | 0.73 | TP53 (0.66) | MEN1KMT2APOLBTP53LMNA | |
| SCHEMBL25010388 | 0.73 | TP53 (0.71) | MEN1KMT2APOLBTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | MEN1 2504/4885KMT2A 2885/4885ALDH1A1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.